Drug intelligence / Profile preview

CLT-28643

Development stage: Preclinical
Lead developer: Clanotech
Modality: Small Molecules
Administration: Subconjunctival, Ophthalmic (topical)

Overview

CLT-28643 is a novel synthetic small molecule that acts as a highly specific antagonist of the α5β1-integrin. It inhibits integrin-mediated fibrosis, angiogenesis, and inflammation. Its primary indication is the prevention of scarring (fibrosis) following glaucoma filtration surgery, aiming to improve surgical outcomes by reducing wound healing–induced blockage of aqueous drainage[1][5][7][9]. Preclinical data show anti-angiogenic, anti-fibrotic, and anti-inflammatory activity, with preferential application in ophthalmology, particularly glaucoma and age-related macular degeneration[5][7][8][9]. Development for cancer was discontinued (see development_status).

Other names: CLT-28643CLT28643CLT 28643CL 28643CL28643CL-28643

Targets

ITGA5:ITGB1 (Integrin α5β1)

Beyond the preview

Go deeper on CLT-28643.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLT-28643.

Explore the full profile